This announcement is long overdue and should be well received by the markets.
 
Sarorius' commitment to provide the equipment  and consumables for the next 3 years reduces the out of pocket costs for PLI for the refurbishment of the Laval plant (likely several $millions) and the operating expenses until all the BLAs are received from regulatory authorities for the plasma proteins to be manufactured at the plant.
 
Sartorius is also providing all the equipment and consumables for the CNBG plants that have been/will be built in China as well as Hematech's plant in Taiwan. This partnership will also target other emerging markets and use the PLI's Laval facility to showcase the PPPS process and Sartorius' equipment.
 

In sum, this represents a very critical step in the execution of PLI's PPPS strategy. It should open the door to other plasma protein deals being signed with NantPharma and others. 

For the Laval plant, the filing of INDs for the various plasma proteins to be manufactured in Quebec will be a major milestone and signal to the market that a new North American player with the world's best technology is about to enter the plasma products market. These filings are expected late 2013/early 2014.

In the case of China, CNBG should be making its IND filings prior to those to be made by Prometic BioProduction which will also represent major milestones in this partnership.

Things just keep getting better and better. The company is delivering BIG TIME and on time!